Bausch Health to Acquire DURECT, Boost Liver Disease Solutions
July 29, 2025
DURECT’s lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Bausch Health Companies Inc., a global, diversified pharmaceutical company, and DURECT Corporation announced